Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
Study Identifier:
ALXN-MG-501
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
Recruiting
Study Details
Medical Condition
- Unmapped
Study Drug
Date
Dec 2019 - Dec 2029
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years
Study Details
Medical Condition
- Unmapped
Study Drug
Date
Dec 2019 - Dec 2029
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information
Protocol Summary
Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®).
Trial Locations
Location
Status
Location
Clinical Trial Site
Birmingham, Alabama, United States, 35294
Status
Recruiting
Location
Clinical Trial Site
Scottsdale, Arizona, United States, 85251
Status
Recruiting
Location
Clinical Trial Site
Fresno, California, United States, 93710
Status
Recruiting
Location
Clinical Trial Site
Orange, California, United States, 92868
Status
Recruiting
Location
Clinical Trial Site
Rancho Mirage, California, United States, 92270
Status
Recruiting
Location
Clinical Trial Site
Sylmar, California, United States, 91342
Status
Recruiting